Gentamicin Exposure and Sensorineural Hearing Loss in Preterm InfantsReportar como inadecuado

Gentamicin Exposure and Sensorineural Hearing Loss in Preterm Infants - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.


To evaluate the impact of gentamicin exposure on sensorineural hearing loss SNHL in very low birth weight VLBW infants.


Exposure to gentamicin was determined in infants born between 1993 and 2010 at a gestational age < 32 weeks and-or with a birthweight < 1500 g, who presented with SNHL during the first 5 years of life. For each case, we selected two controls matched for gender, gestational age, birthweight, and year of birth.


We identified 25 infants affected by SNHL, leading to an incidence of SNHL of 1.58% in our population of VLBW infants. The proportion of infants treated with gentamicin was 76% in the study group and 70% in controls p = 0.78. The total cumulated dose of gentamicin administered did not differ between the study group median 10.2 mg-kg, Q1-Q3 1.6–13.2 and the control group median 7.9 mg-kg, Q1-Q3 0–12.8, p = 0.47. The median duration of gentamicin treatment was 3 days both in the study group and the control group p = 0.58. Maximum predicted trough serum levels of gentamicin, cumulative area under the curve and gentamicin clearance were not different between cases and controls.


The impact of gentamicin on SNHL can be minimized with treatments of short duration, monitoring of blood levels and dose adjustment.

Autor: Aline Fuchs, Lara Zimmermann, Myriam Bickle Graz, Jacques Cherpillod, Jean-François Tolsa, Thierry Buclin, Eric Giannoni



Documentos relacionados